Dr. Lowell Anthony: Use of Telotristat Etiprate in Patients With Carcinoid Syndrome
Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristat etiprate in patients with inadequately controlled carcinoid syndrome.
Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate etiprate in patients with inadequately controlled carcinoid syndrome. Anthony says oncologists now have a new option for patients with carcinoid syndrome, which no longer responds to somatostatin analogs.
The trial was a prospective, randomized, placebo-controlled trial enrolled more than 100 patients, one-third of which received placebos. Patients reported symptoms mainly consisting of diarrhea and the frequency of it, physical function, and impact these symptoms had on their quality of life. Of the 35 participants, 14 patients did not report any signs of improvement, 7 patients had somewhat improvement, and 12 had definite improvement. The reduction in diarrhea allowed for better quality of life, Anthony adds.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
